# Drug Therapies Identified through Modeling AT Deficiency in C Elegans

> **NIH NIH P01** · WASHINGTON UNIVERSITY · 2020 · $418,366

## Abstract

PROJECT SUMMARY
α1-antitrypsin (AT) deficiency (ATD) is the most common genetic cause of liver disease. The classical form of
ATD is due to a single missense mutation (Z) that causes the mutant protein (ATZ) to misfold and accumulate
within the endoplasmic reticulum (ER) of liver cells as toxic oligomers, polymers or aggregates. However, due
to genetic and environmental modifiers, there is marked variation in the incidence and severity of liver disease
among homozygotes. Since the only treatment for severe ATZ-induced hepatic injury is liver transplantation,
we developed an animal model amenable to pre-clinical, high-throughput drug screening technologies that
greatly assists in the discovery of new compounds that reduce or eliminate ATZ-induced hepatotoxicity. The
value of the model would be markedly increased because it also possesses genetic tractability to: 1) elucidate
the genetic modifiers of both tissue damage and the endogenous proteostasis pathways that protect against
protein misfolding-induced injury, and 2) pinpoint which biochemical pathways and/or molecules are targeted
by newly discovered compounds. We show that ATZ-induced liver disease is modeled faithfully in the
nematode, C. elegans. Transgenic animals expressing wild-type human AT secreted the protein. In contrast,
animals expressing ATZ faithfully recapitulated the ER-trafficking defect of ATZ by demonstrating intracellular
inclusions (dilated ER cisterna), and becoming unhealthy as shown by slow growth, small brood sizes and
decreased longevity. Using this model we developed an automated, live-animal, high-content screening (HCS)
assay that rivals that of any cell-based system. So far we have identified ~30 hit compounds, including several
that reduced ATZ accumulation by enhancing autophagy, a known pathway of ATZ elimination. Using a
modification of our HCS strategy, we also developed a semi-automated technology that reduces the labor
intensiveness of genome-wide RNAi screens. We identified several potential genetic modifiers/pathways of
ATZ accumulation. Taken together, these studies demonstrated that this transgenic C. elegans model is a
powerful platform to initiate the discovery of both novel drugs and genes that modify ATZ hepatotoxicity. The
aims of Project 2 are to discover additional hit compounds for the treatment of ATZ-induced disease
phenotypes in C. elegans by both HCS and computer-aided molecular modeling, identify disease modifiers of
major and minor effect, and to determine whether different mutant disease modifiers alter responsiveness to
therapeutic compounds.

## Key facts

- **NIH application ID:** 9994906
- **Project number:** 5P01DK096990-07
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** GARY ARTHUR SILVERMAN
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $418,366
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9994906

## Citation

> US National Institutes of Health, RePORTER application 9994906, Drug Therapies Identified through Modeling AT Deficiency in C Elegans (5P01DK096990-07). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9994906. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*